A Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year after Kidney Transplantation.

BACKGROUND Bone and mineral disorders commonly affect kidney transplant (KTx) recipients and have been associated with a high risk of fracture. Bisphosphonates may prevent or treat bone loss in such patients, but there is concern that these drugs might induce adynamic bone disease (ABD). METHODS In an open label, randomized trial to assess the safety and efficacy of zoledronate for preventing bone loss in the first year after kidney transplant, we randomized 34 patients before transplant to receive zoledronate or no treatment. We used dual-energy x-ray absorptiometry (DXA), high-resolution peripheral quantitative computed tomography (HR-pQCT), and bone biopsies to evaluate changes in bone in the 32 evaluable participants between the time of KTx and 12 months post-transplant. RESULTS Both groups of patients experienced decreased bone turnover after KTx, but zoledronate itself did not affect this outcome. Unlike previous studies, DXA showed no post-transplant bone loss in either group; we instead observed an increase of bone mineral density in both lumbar spine and total hip sites, with a significant positive effect of zoledronate. However, bone biopsies showed post-transplant impairment of trabecular connectivity (and no benefit from zoledronate); HR-pQCT detected trabecular bone loss at the peripheral skeleton, which zoledronate partially attenuated. CONCLUSIONS Current immunosuppressive regimens do not contribute to post-transplant central skeleton trabecular bone loss, and zoledronate does not induce ABD. Because fractures in transplant recipients are most commonly peripheral fractures, clinicians should consider bisphosphonate use in patients at high fracture risk who have evidence of significantly low bone mass at these sites at the time of KTx.

[1]  R. Pereira,et al.  Age-related reference curves of volumetric bone density, structure, and biomechanical parameters adjusted for weight and height in a population of healthy women: an HR-pQCT study , 2017, Osteoporosis International.

[2]  R. Pereira,et al.  Biopsy vs. peripheral computed tomography to assess bone disease in CKD patients on dialysis: differences and similarities , 2017, Osteoporosis International.

[3]  R. Eastell,et al.  Bone Disease after Kidney Transplantation. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[4]  E. Bonfá,et al.  Bone impairment assessed by HR-pQCT in juvenile-onset systemic lupus erythematosus , 2016, Osteoporosis International.

[5]  T. Fehr,et al.  Effect of Twice‐Yearly Denosumab on Prevention of Bone Mineral Density Loss in De Novo Kidney Transplant Recipients: A Randomized Controlled Trial , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  E. Shane,et al.  Longitudinal HR‐pQCT and Image Registration Detects Endocortical Bone Loss in Kidney Transplantation Patients , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  S. Cremers,et al.  Kidney transplantation with early corticosteroid withdrawal: paradoxical effects at the central and peripheral skeleton. , 2014, Journal of the American Society of Nephrology : JASN.

[8]  V. Jorgetti,et al.  Persistence of Bone and Mineral Disorders 2 Years After Successful Kidney Transplantation , 2013, Transplantation.

[9]  Inge Christoffer Olsen,et al.  A 1‐Year Randomized, Double‐Blind, Placebo‐Controlled Study of Intravenous Ibandronate on Bone Loss Following Renal Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  H. Cohen,et al.  Effect of risedronate on bone in renal transplant recipients. , 2012, Journal of the American Society of Nephrology : JASN.

[11]  C. Hollenbeak,et al.  Reduced Fracture Risk With Early Corticosteroid Withdrawal After Kidney Transplant , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  H. Malluche,et al.  Renal osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and white patients , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  M. Yaqoob,et al.  Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  C. Buchpiguel,et al.  Validation of plasma clearance of 51Cr‐EDTA in adult renal transplant recipients: comparison with inulin renal clearance , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[15]  G. Eknoyan,et al.  Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2006, Kidney international.

[16]  N. Heussen,et al.  EARLY RAPID LOSS FOLLOWED BY LONG-TERM CONSOLIDATION CHARACTERIZES THE DEVELOPMENT OF LUMBAR BONE MINERAL DENSITY AFTER KIDNEY TRANSPLANTATION , 2004, Transplantation.

[17]  W. Leslie,et al.  Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate , 2003, Transplantation.

[18]  H. Malluche,et al.  Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. , 2003, Journal of the American Society of Nephrology : JASN.

[19]  K. Hruska,et al.  The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. , 2003, Kidney international.

[20]  R. Oberbauer,et al.  Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. , 2003, Kidney international.

[21]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  H. Malluche,et al.  Bone disease after renal transplantation , 2010, Nature Reviews Nephrology.

[23]  R. Pereira,et al.  Improvement of adynamic bone disease after renal transplantation. , 2006, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[24]  R. Pereira,et al.  Reversal of aluminum-related bone disease after renal transplantation. , 1993, American journal of nephrology.